Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Potentiating drug interaction? 10 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Potentiating drug interaction have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 0.0% of all adverse event reports for DOXORUBICIN.

10
Reports of Potentiating drug interaction with DOXORUBICIN
0.0%
of all DOXORUBICIN reports
1
Deaths
7
Hospitalizations

How Dangerous Is Potentiating drug interaction From DOXORUBICIN?

Of the 10 reports, 1 (10.0%) resulted in death, 7 (70.0%) required hospitalization, and 3 (30.0%) were considered life-threatening.

Is Potentiating drug interaction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Potentiating drug interaction?

METFORMIN (150) METHOTREXATE (119) QUETIAPINE (98) ASPIRIN (87) RIVAROXABAN (71) PREGABALIN (67) TACROLIMUS (56) AMIODARONE (53) CLARITHROMYCIN (52) GABAPENTIN (52)

Which DOXORUBICIN Alternatives Have Lower Potentiating drug interaction Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Potentiating drug interaction Reports All Drugs Causing Potentiating drug interaction DOXORUBICIN Demographics